AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32598243
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic + additional dose i.v. antibiotic
Trial: 32598243
Drug: Prophylaxis +
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis + additional dose i.v. antibiotic + oral antibiotic
Trial: 33539750
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy
Trial: 33539750
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of pertuzumab and trastuzumab
Trial: 35045735
Drug: 8 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 sessions of weekly, individualized, lifestyle education (diet and PA) with behavior change and social support delivered predominantly by telehealth.
Trial: 32869593
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (levofloxacin eye drops and gel)
Trial: 34739194
Drug: Daprodustat (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daprodustat (oral HIF-PHI)
Trial: 33040811
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three orthodontic treatments
Trial: 36201240
Drug: Nabilone (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (1-2 mg, oral)
Trial: 33727311
Drug: Escalation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation of therapy in 94 patients
Trial: 36175997
Drug: green‐MED diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: green‐MED diet (100 g frozen cubes/day of Wolffia globosa, 3-4 cups/day of green tea, 28 g/day of walnuts)
Trial: 36175997
Drug: MED diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MED diet (28 g/day of walnuts)
Trial: 32228720
Drug: Internal TCM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal TCM treatment for mild-to-moderate plaque psoriasis
Trial: 32228720
Drug: External TCM
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: External TCM treatment for mild-to-moderate plaque psoriasis
Trial: 32228720
Drug: TCM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM treatment for severe plaque psoriasis
Trial: 32228720
Drug: WM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WM treatment for severe plaque psoriasis
Trial: 32228720
Drug: TCM +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCM + WM treatment for severe plaque psoriasis
Trial: 36412412
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 400 mcg given 3 hours prior to the procedure
Trial: 32391881
Drug: Adjunctive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive oral cannabidiol
Trial: 35264510
Drug: Palatal brushing
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palatal brushing and standard oral/denture hygiene
Trial: 35264510
Drug: Standard oral/denture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral/denture hygiene instructions only
Trial: 32964717
Drug: Furosemide (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (0.2 to 0.5 mg/kg as a continuous intravenous infusion for 24 hours postoperatively)
Trial: 32964717
Drug: Furosemide combined
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide combined with standard hydration therapy
Trial: 32962709
Drug: CHF6001 400,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF6001 400, 800, 1200 or 1600 μg twice daily (BID)
Trial: 32962709
Drug: CHF6001 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF6001 800 and 1600 μg BID
Trial: 34936167
Drug: Vaporized cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaporized cannabis containing 13.75 mg THC
Trial: 32115392
Drug: Medication education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication education and management
Trial: 32115392
Drug: Non‐medication‐related patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐medication‐related patient education
Trial: 33459183
Drug: Adaptive design
RxNorm normalized name: Designer Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive design integrating dose finding and confirmation steps
Trial: 34559230
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of FRM-0334
Trial: 34559230
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of FRM-0334
Trial: 34559230
Drug: FRM-0334 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FRM-0334 (both doses)
Trial: 34985771
Drug: Online intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online intervention supporting couples' posttreatment recovery of sexual intimacy, comprising 6 modules addressing expectations for sexual and emotional sequelae of treatment, rehabilitation, and guidance toward sexual intimacy recovery.
Trial: 32783330
Drug: Topical PR
RxNorm normalized name: Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical PR gel under the left orbit once a day and topical plus nano‐microneedle‐assisted PR gel under the right orbit twice a week
Trial: 32783330
Drug: Gel without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel without PR (Control)
Trial: 34427049
Drug: ASP5354 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP5354 0.1 mg
Trial: 34427049
Drug: ASP5354 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP5354 (0.1 mg to 24 mg)
Trial: 33484515
Drug: Core stability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core stability exercises along with traditional therapy
Trial: 33484515
Drug: Traditional low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional low backache physical therapy
Trial: 34138468
Drug: Intravenous polyspecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous polyspecific immunoglobulin G (IVIG) 25 g/d for 3 days
Trial: 33225782
Drug: Isosorbide‐5‐mononitrate capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate capsule
Trial: 35965813
Drug: Zengxiao Jiandu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zengxiao Jiandu decoction combined with definitive concurrent chemoradiotherapy (DCCRT)
Trial: 32561468
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (40 IU) administered prior to each PE therapy session
Trial: 32561468
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered prior to each PE therapy session
Trial: 36421994
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Whole PT and SupB (A+SupB)
Trial: 32220355
Drug: Curcumin 500
RxNorm normalized name: curcumin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 500 mg/day for 12 weeks
Trial: 33729546
Drug: FOLFOX (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX (all three agents)
Trial: 34126156
Drug: REGN5713/14/15 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN5713/14/15 (900 mg)
Trial: 33394214
Drug: Lansoprazole (LAN)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LAN) 60 mg p.o. bid for one week before starting each cycle + R‐CHOP
Trial: 33394214
Drug: Famotidine (FAM)
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine (FAM) 40 mg p.o. once daily one week before cycle and continues daily through the cycle + R‐CHOP for six cycles
Trial: 33394214
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received R‐CHOP standard chemotherapy
Trial: 35690876
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (standard model of care delivered by the Justice Health and Forensic Mental Health Network)
Trial: 32267847
Drug: First-line antiretroviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line antiretroviral therapy
Trial: 35292944
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (80 mg) and calcium (1 g) daily
Trial: 36301511
Drug: Intravenous caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous caffeine (20 mg/kg)
Trial: 36301511
Drug: Enteral caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral caffeine (20 mg/kg)
Trial: 33277284
Drug: Intravenous caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous caffeine
Trial: 32469385
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg/d for 36 months
Trial: 32469385
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg/d for 12 months
Trial: 35193873
Drug: MTX-hold (2-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX-hold (2-week methotrexate discontinuation after each vaccine dose)
Trial: 35639672
Drug: LifeBuoy (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LifeBuoy (therapeutic smartphone application based on dialectical behavior therapy)
Trial: 32499466
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 1.2 g amoxicillin‐clavulanic acid
Trial: 32499466
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days course of amoxicillin‐clavulanic acid and metronidazole
Trial: 34635373
Drug: Currently licensed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Currently licensed MenACWY-CRM vaccine presentation
Trial: 35149125
Drug: Peg‐IFN‐α‐based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN‐α‐based therapy for 96 weeks with 24-week off-treatment follow-up
Trial: 35149125
Drug: Peg‐IFN‐α‐based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN‐α‐based therapy
Trial: 35149125
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HBcrAg <4 log10U/ml and HBsAb >2 log10IU/L at EOT
Trial: 34960153
Drug: Revaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revaccination with one dose of hepatitis B vaccine containing 60 µg HBsAg
Trial: 34960153
Drug: Revaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revaccination with one dose of hepatitis B vaccine containing 20 µg HBsAg
Trial: 34791503
Drug: Peer-led oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-led oral health intervention based on Health Belief Model and Social Cognitive Theory
Trial: 33678183
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml ABHR volume
Trial: 33678183
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml ABHR volume
Trial: 33678183
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml ABHR volume
Trial: 33678183
Drug: 1.5 ml
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml ABHR volume
Trial: 33678183
Drug: 3.5 ml
RxNorm normalized name: ethanol 3.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 ml or more ABHR volume
Trial: 35888587
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation treatment (2 sessions per day for 90 min, 5 days a week)
Trial: 32702190
Drug: Studies for
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Studies for first-line therapy
Trial: 35410967
Drug: Prednisolone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (15 mg/m2 daily for 6 days)
Trial: 33590829
Drug: Upadacitinib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib (15 mg QD)
Trial: 33371023
Drug: Physitrack online
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physitrack online exercise prescription tool
Trial: 35526026
Drug: Tanreqing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanreqing oral liquid, 20 mL three times daily for seven consecutive days
Trial: 35526026
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral liquid, 20 mL three times daily for seven consecutive days
Trial: 35276914
Drug: Lactococcus lactis
RxNorm normalized name: Lactococcus Lactis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactococcus lactis strain Plasma (LC‐Plasma) administered as a beverage (1.0 × 10^11 count LC‐Plasma/day/person)
Trial: 33101559
Drug: LED light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED light therapy with electromagnetic field (MLT)
Trial: 33612629
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Nutrition Education and Multi-Nutrient Biscuits (NE+MNB)
Trial: 33023221
Drug: Low Protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Protein (LP) - 15 g protein
Trial: 33023221
Drug: Medium Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Protein (MP) - 30 g protein
Trial: 33023221
Drug: High Protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Protein (HP) - 45 g protein
Trial: 33023221
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - 7 g protein
Trial: 33615957
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with cTACE + MWA (Group 3)
Trial: 35865817
Drug: Empirical intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical intravenous antibiotic therapy during endotherapy (Group 1)
Trial: 35865817
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic therapy during endoscopic drainage (Group 2)
Trial: 35578271
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration with a target of 2–2.5 times baseline aPTT
Trial: 35578271
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration with a target of 1.5–2 times baseline aPTT
Trial: 35578271
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin guided by weight and renal function
Trial: 33259725
Drug: Standardized Tinnitus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized Tinnitus Retraining Therapy (TRT)
Trial: 33831327
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (200 micrograms, orally administered, 4 times daily for 8 weeks)
Trial: 34271853
Drug: Hydromorphone hydrochloride
RxNorm normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone hydrochloride 0.1 mg/kg (H1)
Trial: 34271853
Drug: Hydromorphone hydrochloride
RxNorm normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone hydrochloride 0.2 mg/kg (H2)
Trial: 34271853
Drug: Sufentanil 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 1.5 µg/kg (S)
Trial: 33099662
Drug: P. fluorescens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. fluorescens and P. indica (alone or in combination)
Trial: 33099662
Drug: P. indica
RxNorm normalized name: Cannabis sativa subsp. indica top
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. indica (alone or in combination with SPB)
Trial: 32729888
Drug: Ranibizumab, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab, 0.5 mg every 4 weeks (arm A)
Trial: 32729888
Drug: Faricimab, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab, 1.5 mg every 4 weeks (arm B)
Trial: 32729888
Drug: Faricimab, 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab, 6.0 mg every 4 weeks (arm C)
Trial: 32729888
Drug: Faricimab, 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab, 6.0 mg every 4 weeks until week 12, then faricimab, 6.0 mg every 8 weeks (arm D)
Trial: 32729888
Drug: Ranibizumab, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab, 0.5 mg every 4 weeks until week 8, then faricimab, 6.0 mg every 4 weeks (arm E)
Trial: 33725857
Drug: Yiqi Liangxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Liangxue Shengji prescription (YLS)
Trial: 33415555
Drug: Nebulized isotonic
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized isotonic magnesium (1024 mg/h)
Trial: 33415555
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (200 mg/kg over 30 min, followed by 50 mg/kg/h)
Trial: 34530112
Drug: 30 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/d of 85% cocoa chocolate (DC85)
Trial: 34635353
Drug: Copper and
RxNorm normalized name: Copper and/or copper compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper and zinc chelate gel (coppergel)
Trial: 33840773
Drug: Varenicline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (up to 2 mg daily)
Trial: 33999270
Drug: Dignity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity therapy (N = 32)
Trial: 39606414
Drug: mTOR inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR inhibitors
Trial: 35550508
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance chemotherapy
Trial: 32112496
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (CBT) for 14 weeks
Trial: 616625620
Drug: Ginseng extract
RxNorm normalized name: ginseng extract
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng extract (300 mg)
Trial: 34412166
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg pure CBD
Trial: 34412166
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg pure CBD
Trial: 34412166
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg pure CBD
Trial: 33745898
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy (IMT) including high-intensity statins and ACE-I or ARB
Trial: 33617367
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment condition (control)
Trial: 36908150
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg pitavastatin
Trial: 35732378
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment by IAPT therapists
Trial: 39075156
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT)
Trial: 35808889
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol